Cha Yong-Mei, Rea Robert F, Wang Ming, Shen Win-Kuang, Asirvatham Samuel J, Friedman Paul A, Munger Thomas M, Espinosa Raul E, Hodge David O, Hayes David L, Redfield Margaret M
Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
J Cardiovasc Electrophysiol. 2007 Sep;18(10):1015-9. doi: 10.1111/j.1540-8167.2007.00926.x. Epub 2007 Aug 16.
To determine whether survival after cardiac resynchronization therapy (CRT) is related to improvement in clinical or echocardiographic parameters.
In clinical trials, CRT improved symptoms, left ventricular (LV) structure, function, and survival. In clinical practice, response to CRT is highly variable and whether survival benefit is confined to those patients who experience improvement in clinical status or cardiac structure and function is unclear.
This is a single-center study of patients receiving clinically indicated CRT between January 2002 and December 2004.
Of 309 patients (age 68 +/- 11 years, 83% male) receiving CRT at our institution during the study period, 174 returned for follow-up and 127 had repeat echocardiography. Baseline clinical characteristics and survival were similar among those who did or did not return for follow-up. In paired analyses, New York Heart Association (NYHA) class (-0.56 +/- 0.07, p < 0.0001), ejection fraction (EF, 6.3 +/- 0.7%, P < 0.0001), LV dimension (-2.7 +/- 0.6 mm, P < 0.0001), pulmonary artery systolic pressure (PASP, -4.6 +/- 1.3 mm Hg, P = 0.0007), and MR severity grade (-0.20 +/- 0.05, P = 0.0002) improved after CRT. Survival after CRT was associated with decrease in NYHA class (risk ratio [RR]= 0.43, P = 0.0004), increase in EF (RR = 0.94, P = 0.02), and decrease in PASP (RR = 0.96, P = 0.03). Change in EF and NYHA class were correlated (r = -0.46, P < 0.0001) and, adjusting for this covariance, change in NYHA (P = 0.04) but not EF (P = 0.12) was associated with improved survival.
Patients who experience improved symptoms, ventricular function, and/or hemodynamics have better survival after CRT. These data enhance understanding of the relationship between CRT clinical response and survival benefit in clinical practice.
确定心脏再同步治疗(CRT)后的生存率是否与临床或超声心动图参数的改善有关。
在临床试验中,CRT改善了症状、左心室(LV)结构、功能和生存率。在临床实践中,对CRT的反应差异很大,生存获益是否仅限于临床状态或心脏结构与功能得到改善的患者尚不清楚。
这是一项对2002年1月至2004年12月期间接受临床指征CRT治疗的患者进行的单中心研究。
在研究期间,我院309例接受CRT治疗的患者(年龄68±11岁,83%为男性)中,174例返回进行随访,127例进行了重复超声心动图检查。随访和未随访患者的基线临床特征和生存率相似。在配对分析中,纽约心脏协会(NYHA)分级(-0.56±0.07,p<0.0001)、射血分数(EF,6.3±0.7%,P<0.0001)、左心室尺寸(-2.7±0.6mm,P<0.0001)、肺动脉收缩压(PASP,-4.6±1.3mmHg,P=0.0007)和二尖瓣反流严重程度分级(-0.20±0.05,P=0.0002)在CRT后有所改善。CRT后的生存率与NYHA分级降低(风险比[RR]=0.43,P=0.0004)、EF升高(RR=0.94,P=0.02)和PASP降低(RR=0.96,P=0.03)相关。EF和NYHA分级的变化具有相关性(r=-0.46,P<0.0001),在调整此协变量后,NYHA分级的变化(P=0.04)而非EF的变化(P=0.12)与生存率提高相关。
症状、心室功能和/或血流动力学得到改善的患者在CRT后生存率更高。这些数据增进了对临床实践中CRT临床反应与生存获益之间关系的理解。